Sirolimus as Primary Treatment of Acute Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation
Authors:
- Joseph PidalaJPJoseph Pidala
- Jongphil KimJKJongphil Kim
- Claudio AnasettiCAClaudio Anasetti
Open Access
- 1 July 2009
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 15 (7) , 881-885
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity ConditioningJournal of Clinical Oncology, 2008
- Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host diseaseBlood, 2008
- A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell TransplantationTransplantation and Cellular Therapy, 2008
- Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantationBlood, 2006
- Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cellsBlood, 2006
- Prophylaxis and Treatment of Acute Graft-Versus-Host DiseaseSeminars in Hematology, 2006
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2005
- Putting the Rap on AktJournal of Clinical Oncology, 2004
- Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trialBlood, 2004
- The Phosphoinositide 3-Kinase PathwayScience, 2002